GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gritstone Bio Inc (NAS:GRTS) » Definitions » Total Current Liabilities

Gritstone Bio (Gritstone Bio) Total Current Liabilities : $25.87 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Gritstone Bio Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Gritstone Bio's total current liabilities for the quarter that ended in Mar. 2024 was $25.87

Gritstone Bio Total Current Liabilities Historical Data

The historical data trend for Gritstone Bio's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gritstone Bio Total Current Liabilities Chart

Gritstone Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial 19.50 26.99 39.96 34.80 27.34

Gritstone Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.67 22.11 23.38 27.34 25.87

Gritstone Bio Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Gritstone Bio's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=8.728+6.904
+Other Current Liabilities+Current Deferred Liabilities
=9.357+2.35
=27.34

Gritstone Bio's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=13.434+6.811
+Other Current Liabilities+Current Deferred Liabilities
=4.34+1.285
=25.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Gritstone Bio Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Gritstone Bio's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gritstone Bio (Gritstone Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gritstone Bio Inc (NAS:GRTS) » Definitions » Total Current Liabilities
Comparable Companies
IVVD DNTH CBUS PSTX MACK CRMD INZY IMRX AEON RENB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
2JQ:Germany 2JQ:Germany
Address
5959 Horton Street, Suite 300, Emeryville, CA, USA, 94608
Website
https://gritstonebio.com
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, BiSAb, among others.
Executives
Lawrence Corey director C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Naiyer Rizvi director C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Clare Fisher director C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Steve E. Krognes director 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Shefali Agarwal director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Vassiliki Economides officer: See Remarks C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Erin Jones officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
James Cho officer: Chief Accounting Officer C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Raphael Rousseau officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Roman Yelensky officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Thomas Woiwode director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rahsaan Thompson officer: EVP and General Counsel 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Vijay Yabannavar officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Nicholas Simon director 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142

Gritstone Bio (Gritstone Bio) Headlines

From GuruFocus

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Marketwired • 09-13-2023

Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

By Marketwired • 08-09-2023

Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023

By Marketwired • 10-04-2023

Gritstone bio and Genevant Sciences Announce Option and License Agreement

By Marketwired • 08-15-2023

Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project

By Marketwired • 08-07-2023

Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)

By sperokesalga sperokesalga • 04-17-2023

Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination

By sperokesalga sperokesalga • 02-14-2023

Gritstone bio to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 11, 2023

By sperokesalga sperokesalga • 05-03-2023

Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio's BARDA Award

By Marketwired • 10-12-2023

Gritstone bio to Participate in 43rd Annual Cowen Healthcare Conference

By sperokesalga sperokesalga • 02-27-2023